世界の二次性副甲状腺機能亢進症薬市場レポート2020年

QYResearchが発行した調査報告書(QYR21FB12889)
◆英語タイトル:Global Secondary Hyperparathyroidism Drug Sales Market Report 2020
◆商品コード:QYR21FB12889
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年1月(※2024年版があります。お問い合わせください。)
◆ページ数:133
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品、医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD8,000 ⇒換算¥1,184,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

QYリサーチ社の本調査レポートでは、世界の二次性副甲状腺機能亢進症薬市場について種類別(エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他)、用途別(病院、診療所、その他)、地域別(アメリカ、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。
・二次性副甲状腺機能亢進症薬市場の概要
・世界の主要地域別二次性副甲状腺機能亢進症薬市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界の二次性副甲状腺機能亢進症薬市場規模2015-2026:種類別(エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他)
・世界の二次性副甲状腺機能亢進症薬市場規模2015-2026:用途別(病院、診療所、その他)
・二次性副甲状腺機能亢進症薬のアメリカ市場規模2015-2020
・二次性副甲状腺機能亢進症薬のヨーロッパ市場規模2015-2020
・二次性副甲状腺機能亢進症薬の中国市場規模2015-2020
・二次性副甲状腺機能亢進症薬の日本市場規模2015-2020
・二次性副甲状腺機能亢進症薬の東南アジア市場規模2015-2020
・二次性副甲状腺機能亢進症薬のインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
・二次性副甲状腺機能亢進症薬の製造コスト分析
・販売チャネル、流通業者、顧客
・二次性副甲状腺機能亢進症薬の市場動向・機会・課題
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Secondary Hyperparathyroidism Drug Market
The global Secondary Hyperparathyroidism Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Secondary Hyperparathyroidism Drug Scope and Market Size
The global Secondary Hyperparathyroidism Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Secondary Hyperparathyroidism Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Secondary Hyperparathyroidism Drug market is segmented into
Evocalcet
LNP-1892
AJT-240
Cinacalcet Hydrochloride
CTA-091
Others

Segment by Application, the Secondary Hyperparathyroidism Drug market is segmented into
Hospital
Clinic
Others

The Secondary Hyperparathyroidism Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Secondary Hyperparathyroidism Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Secondary Hyperparathyroidism Drug Market Share Analysis
Secondary Hyperparathyroidism Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Secondary Hyperparathyroidism Drug business, the date to enter into the Secondary Hyperparathyroidism Drug market, Secondary Hyperparathyroidism Drug product introduction, recent developments, etc.

The major vendors covered:
Deltanoid Pharmaceuticals Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Takeda

【レポートの目次】

1 Secondary Hyperparathyroidism Drug Market Overview
1.1 Secondary Hyperparathyroidism Drug Product Scope
1.2 Secondary Hyperparathyroidism Drug Segment by Type
1.2.1 Global Secondary Hyperparathyroidism Drug Sales by Type (2020-2026)
1.2.2 Evocalcet
1.2.3 LNP-1892
1.2.4 AJT-240
1.2.5 Cinacalcet Hydrochloride
1.2.6 CTA-091
1.2.7 Others
1.3 Secondary Hyperparathyroidism Drug Segment by Application
1.3.1 Global Secondary Hyperparathyroidism Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Secondary Hyperparathyroidism Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Secondary Hyperparathyroidism Drug Sales Growth Rate (2015-2026)
1.4.2 Global Secondary Hyperparathyroidism Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Secondary Hyperparathyroidism Drug Price Trends (2015-2026)

2 Secondary Hyperparathyroidism Drug Estimate and Forecast by Region
2.1 Global Secondary Hyperparathyroidism Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Secondary Hyperparathyroidism Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Secondary Hyperparathyroidism Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Secondary Hyperparathyroidism Drug Revenue Market Share by Region (2015-2020)
2.3 Global Secondary Hyperparathyroidism Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Secondary Hyperparathyroidism Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Secondary Hyperparathyroidism Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
2.4.2 Europe Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
2.4.3 China Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
2.4.4 Japan Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
2.4.6 India Secondary Hyperparathyroidism Drug Estimates and Projections (2015-2026)
3 Global Secondary Hyperparathyroidism Drug Competition Landscape by Players
3.1 Global Top Secondary Hyperparathyroidism Drug Players by Sales (2015-2020)
3.2 Global Top Secondary Hyperparathyroidism Drug Players by Revenue (2015-2020)
3.3 Global Secondary Hyperparathyroidism Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Secondary Hyperparathyroidism Drug as of 2019)
3.4 Global Secondary Hyperparathyroidism Drug Average Price by Company (2015-2020)
3.5 Manufacturers Secondary Hyperparathyroidism Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Secondary Hyperparathyroidism Drug Players (Opinion Leaders)
4 Global Secondary Hyperparathyroidism Drug Market Size by Type
4.1 Global Secondary Hyperparathyroidism Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Secondary Hyperparathyroidism Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Secondary Hyperparathyroidism Drug Price by Type (2015-2020)
4.2 Global Secondary Hyperparathyroidism Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Secondary Hyperparathyroidism Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Secondary Hyperparathyroidism Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Secondary Hyperparathyroidism Drug Price Forecast by Type (2021-2026)
5 Global Secondary Hyperparathyroidism Drug Market Size by Application
5.1 Global Secondary Hyperparathyroidism Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Secondary Hyperparathyroidism Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Secondary Hyperparathyroidism Drug Price by Application (2015-2020)
5.2 Global Secondary Hyperparathyroidism Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Secondary Hyperparathyroidism Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Secondary Hyperparathyroidism Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Secondary Hyperparathyroidism Drug Price Forecast by Application (2021-2026)

6 United States Secondary Hyperparathyroidism Drug Market Facts & Figures
6.1 United States Secondary Hyperparathyroidism Drug Sales Market Share by Company (2015-2020)
6.2 United States Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
6.3 United States Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

7 Europe Secondary Hyperparathyroidism Drug Market Facts & Figures
7.1 Europe Secondary Hyperparathyroidism Drug Sales Market Share by Company (2015-2020)
7.2 Europe Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
7.3 Europe Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

8 China Secondary Hyperparathyroidism Drug Market Facts & Figures
8.1 China Secondary Hyperparathyroidism Drug Sales Market Share by Company (2015-2020)
8.2 China Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
8.3 China Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

9 Japan Secondary Hyperparathyroidism Drug Market Facts & Figures
9.1 Japan Secondary Hyperparathyroidism Drug Sales Market Share by Company (3015-3030)
9.2 Japan Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
9.3 Japan Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

10 Southeast Asia Secondary Hyperparathyroidism Drug Market Facts & Figures
10.1 Southeast Asia Secondary Hyperparathyroidism Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

11 India Secondary Hyperparathyroidism Drug Market Facts & Figures
11.1 India Secondary Hyperparathyroidism Drug Sales Market Share by Company (2015-2020)
11.2 India Secondary Hyperparathyroidism Drug Sales Market Share by Type (2015-2020)
11.3 India Secondary Hyperparathyroidism Drug Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Secondary Hyperparathyroidism Drug Business
12.1 Deltanoid Pharmaceuticals Inc
12.1.1 Deltanoid Pharmaceuticals Inc Corporation Information
12.1.2 Deltanoid Pharmaceuticals Inc Business Overview
12.1.3 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Products Offered
12.1.5 Deltanoid Pharmaceuticals Inc Recent Development
12.2 EA Pharma Co Ltd
12.2.1 EA Pharma Co Ltd Corporation Information
12.2.2 EA Pharma Co Ltd Business Overview
12.2.3 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Products Offered
12.2.5 EA Pharma Co Ltd Recent Development
12.3 Lupin Ltd
12.3.1 Lupin Ltd Corporation Information
12.3.2 Lupin Ltd Business Overview
12.3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Lupin Ltd Secondary Hyperparathyroidism Drug Products Offered
12.3.5 Lupin Ltd Recent Development
12.4 Mitsubishi Tanabe Pharma Corp
12.4.1 Mitsubishi Tanabe Pharma Corp Corporation Information
12.4.2 Mitsubishi Tanabe Pharma Corp Business Overview
12.4.3 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Products Offered
12.4.5 Mitsubishi Tanabe Pharma Corp Recent Development
12.5 OPKO Health Inc
12.5.1 OPKO Health Inc Corporation Information
12.5.2 OPKO Health Inc Business Overview
12.5.3 OPKO Health Inc Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 OPKO Health Inc Secondary Hyperparathyroidism Drug Products Offered
12.5.5 OPKO Health Inc Recent Development
12.6 Takeda
12.6.1 Takeda Corporation Information
12.6.2 Takeda Business Overview
12.6.3 Takeda Secondary Hyperparathyroidism Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Takeda Secondary Hyperparathyroidism Drug Products Offered
12.6.5 Takeda Recent Development

13 Secondary Hyperparathyroidism Drug Manufacturing Cost Analysis
13.1 Secondary Hyperparathyroidism Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Secondary Hyperparathyroidism Drug
13.4 Secondary Hyperparathyroidism Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Secondary Hyperparathyroidism Drug Distributors List
14.3 Secondary Hyperparathyroidism Drug Customers

15 Market Dynamics
15.1 Secondary Hyperparathyroidism Drug Market Trends
15.2 Secondary Hyperparathyroidism Drug Opportunities and Drivers
15.3 Secondary Hyperparathyroidism Drug Market Challenges
15.4 Secondary Hyperparathyroidism Drug Market Restraints
15.5 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

...

【掲載企業】

Deltanoid Pharmaceuticals Inc、EA Pharma Co Ltd、Lupin Ltd、Mitsubishi Tanabe Pharma Corp、OPKO Health Inc、Takeda

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の二次性副甲状腺機能亢進症薬市場レポート2020年(Global Secondary Hyperparathyroidism Drug Sales Market Report 2020)]についてメールでお問い合わせはこちらでお願いします。